RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Shin Nippon Biomedical Laboratories Stock

Shin Nippon Biomedical Laboratories Debt 2025

Shin Nippon Biomedical Laboratories Debt

22,441.9 JPY

Ticker

2395.T

ISIN

JP3379950003

WKN

A0BMJN

In 2025, Shin Nippon Biomedical Laboratories's total debt was 22,441.9 JPY, a 167.2% change from the 8,398.83 JPY total debt recorded in the previous year.

Shin Nippon Biomedical Laboratories Aktienanalyse

What does Shin Nippon Biomedical Laboratories do?

Shin Nippon Biomedical Laboratories Ltd (SNBL) is a Japanese company that was founded in 1957. The company is headquartered in Tokyo, Japan. SNBL is an important player in the research and development industry, offering a wide range of services in the field of biomedical research. SNBL's business strategy is based on providing services to pharmaceutical companies and other medical institutions. The service portfolio includes both the development phase and the approval and post-marketing monitoring of drugs. SNBL offers a comprehensive service in this area, ranging from experimental planning to study implementation, report creation, and results analysis. The company has several geographical offices in Asia, Europe, and America to serve its customers worldwide. SNBL is divided into different divisions specializing in different areas of biomedical research. One important division is the Non-human Primates (NHP) research program. SNBL is able to provide a wide range of NHP species for research, ranging from rhesus monkeys to monkeys from China and Africa. These animals are used for research projects both for drug safety assessment and disease exploration. SNBL is also active in the field of genetic engineering, offering a wide range of services in this area. The company has several cell-based assay systems for drug development and experience in producing recombinant proteins for research. SNBL also offers analysis services for nucleic acids and proteins of all kinds and has extensive expertise in genotyping and gene expression analysis. Another pillar of SNBL's activities is toxicology and safety research. SNBL is a leading provider of toxicology studies, advising its clients on the design of animal safety assessment studies. The company also provides a wide range of non-GLP studies for toxicity evaluations. Additionally, SNBL is able to evaluate the results of toxicology studies and conduct risk analyses for specific products. SNBL also has its own drug development pipeline and has several products in development. One example is Nafamostat Mesilate, a drug being developed for the treatment of acute respiratory distress syndrome and acute pancreatitis. The company works closely with its clients to develop customized solutions for their specific research needs. SNBL's products and services make a significant contribution to the biomedical research industry and have worldwide impact on the healthcare of humans and animals. The company has a long history in the research industry and is recognized as a provider of services for drug development due to its expertise and experience. With its extensive services for biomedical research, SNBL will remain an important player in this field in the future. Shin Nippon Biomedical Laboratories ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Shin Nippon Biomedical Laboratories's Debt Structure

Shin Nippon Biomedical Laboratories's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Shin Nippon Biomedical Laboratories's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Shin Nippon Biomedical Laboratories’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Shin Nippon Biomedical Laboratories’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Shin Nippon Biomedical Laboratories stock

What is the debt of Shin Nippon Biomedical Laboratories this year?

Shin Nippon Biomedical Laboratories has a debt level of 22,441.9 JPY this year.

What was the debt of Shin Nippon Biomedical Laboratories compared to the previous year?

The debt of Shin Nippon Biomedical Laboratories has increased by 167.2% compared to the previous year increased.

What are the consequences of high debt for investors in Shin Nippon Biomedical Laboratories?

High debt can pose a risk for investors of Shin Nippon Biomedical Laboratories, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Shin Nippon Biomedical Laboratories?

Low debt means that Shin Nippon Biomedical Laboratories has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Shin Nippon Biomedical Laboratories affect the company?

An increase in debt of Shin Nippon Biomedical Laboratories can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Shin Nippon Biomedical Laboratories affect the company?

A reduction in debt of Shin Nippon Biomedical Laboratories can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Shin Nippon Biomedical Laboratories?

Some factors that can influence the debt of Shin Nippon Biomedical Laboratories include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Shin Nippon Biomedical Laboratories so important for investors?

The debts of Shin Nippon Biomedical Laboratories are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Shin Nippon Biomedical Laboratories take to change the debt?

To change the debt, Shin Nippon Biomedical Laboratories can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Shin Nippon Biomedical Laboratories pay?

Over the past 12 months, Shin Nippon Biomedical Laboratories paid a dividend of 30 JPY . This corresponds to a dividend yield of about 2.16 %. For the coming 12 months, Shin Nippon Biomedical Laboratories is expected to pay a dividend of 38.87 JPY.

What is the dividend yield of Shin Nippon Biomedical Laboratories?

The current dividend yield of Shin Nippon Biomedical Laboratories is 2.16 %.

When does Shin Nippon Biomedical Laboratories pay dividends?

Shin Nippon Biomedical Laboratories pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Shin Nippon Biomedical Laboratories?

Shin Nippon Biomedical Laboratories paid dividends every year for the past 0 years.

What is the dividend of Shin Nippon Biomedical Laboratories?

For the upcoming 12 months, dividends amounting to 38.87 JPY are expected. This corresponds to a dividend yield of 2.8 %.

In which sector is Shin Nippon Biomedical Laboratories located?

Shin Nippon Biomedical Laboratories is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shin Nippon Biomedical Laboratories kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shin Nippon Biomedical Laboratories from 6/1/2025 amounting to 30 JPY, you needed to have the stock in your portfolio before the ex-date on 3/28/2025.

When did Shin Nippon Biomedical Laboratories pay the last dividend?

The last dividend was paid out on 6/1/2025.

What was the dividend of Shin Nippon Biomedical Laboratories in the year 2024?

In the year 2024, Shin Nippon Biomedical Laboratories distributed 50 JPY as dividends.

In which currency does Shin Nippon Biomedical Laboratories pay out the dividend?

The dividends of Shin Nippon Biomedical Laboratories are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Shin Nippon Biomedical Laboratories

Our stock analysis for Shin Nippon Biomedical Laboratories Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shin Nippon Biomedical Laboratories Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.